Pakistan continues to be dealing with a polio outbreak as four fresh cases have emerged, pushing the national tally to 37 this year, according to health officials on October 19, 2024. Health officials said that the regional reference laboratory for polio eradication at the National Institute of Health in Islamabad confirmed wild poliovirus type-1 (WPV1) in two children-one from each Balochistan and Khyber-Pakhtunkhwa.

In recent cases, a girl has been affected from Pishin, and two boys from Chaman and Noshki of Balochistan, and a girl from Lakki Marwat in KP. These are the first detections of the virus within Noshki and Lakki Marwat this year; isolated cases of poliovirus were previously reported within Chaman and Pishin. The province of Balochistan was the worst hit with 20 cases, Sindh had 10, Khyber Pakhtunkhwa had five, and Punjab and Islamabad had one case each.

A gigantic fight against polio has been on going in Pakistan- especially in Balochistan and southern KP-over the last two years. Immunisation campaigns have often been suspended or delayed because of local protests, insecurity, and community boycotts. Consequently, quite a number of children did not get the necessary vaccinations, making existing patches of vulnerability for the virus to flow within those pockets.

Noshki, located near Afghanistan's border, and Lakki Marwat have also recently reported some positive environmental samples that confirm the virus is present here, said a local reference laboratory official. Samples of latest cases are currently under genetic sequencing for checking spread of virus and origin.

As the threat of polio continues to grow, Pakistan has vowed to mount a nationwide campaign against it beginning from October 28. With the zeal to tackle the menace in the most effective manner, over 45 million children under the age of five will be vaccinated across the country.

Today, Afghanistan and Pakistan remain one of the few countries where polio has not yet been eradicated. The WHO said the virus remains a potential serious public health threat in areas with low vaccination coverage and weak surveillance.

India On Alert Against Polio

The country declared itself polio-free since 2014 and has kept the disease on bay almost a decade with very robust vaccination programs; however, two cases of vaccine-derived poliovirus cases reported in recent days from Meghalaya create some amount of doubts over a possible resurgence. Experts observe that in India, despite these detections taking place, strong coverage of vaccination at 90-95% and mandatory surveillance measures keep the risk of this widespread outbreak at bay.

The experts point out, however, that such stable situation in India requires continued surveillance. "Countries like Pakistan and parts of Africa remain at a high risk because vaccination rates in those areas are much lower," Dr. Siddharth, public health expert, said. Vaccination is an indispensable act in order to avoid the spread of this incapacitating disease that manifests most importantly as a nervous system affliction leading to the paralysis of a long period.

With concerted efforts from health authorities, there is hope someday that the scourge of polio will be completely eradicated from the face of the earth and future generations will never suffer from its effects.

Weight-loss drugs like Ozempic have gained prominence in a short period of time. Now, Ozempic, Mounjaro, and Wegovy have become household names, especially for patients with diabetes and obesity. There is now a new name in the market that is gaining attention, even though it has not yet been approved. Retatrutide is a new injectable peptide that is being described as the next big thing in weight loss. Some are claiming that it might be more powerful than Wegovy or Ozempic, the most popular drugs so far. But what makes it stronger or sets it apart? It is the way Retatrutide works.

What is Retatrutide?

Retatrutide, also known as 'reta,' is a peptide that is currently being tested in clinical trials for weight-loss purposes. Despite not being approved for use anywhere in the world yet, it is making its way through online markets. The peptide is currently in clinical trials. Peptides are short chains of amino acids that can reduce inflammation and aid healing.

How does Retatrutide support weight loss?

For weight loss, retatrutide acts on three hormone pathways that affect metabolism, appetite, and blood sugar levels. GLP-1 is the first hormone, which reduces appetite and slows down the rate at which food leaves the stomach. The second is GIP, which regulates fat storage and blood sugar. The third is glucagon, which manages blood sugar. By working on these three hormones, Retatrutide reduces how much one eats and influences how much fat the body burns.

Read more: Shocking! Study Claims Weight Loss Drugs Cause More Muscle Loss Than Expected

The results from early trials were impressive—retatrutide performed much better for weight loss compared to its counterparts. In a 2023 trial, patients who were given a higher dose of the drug experienced 20 per cent more weight loss over 48 weeks. However, the trials were conducted in controlled clinical settings under medical supervision and on selected patients with regulated dosing. At present, people are buying the drug online and using it without medical supervision.

The effect of Retatrutide on gym-goers

A weekly dose of Retatrutide can support fat loss and suppress appetite. As a result, one can lose a significant amount of weight quickly and appear leaner and more defined, but rapid weight loss does not necessarily mean fat loss. It could also involve muscle mass, especially if one is not consuming enough protein or engaging in resistance training. As a result, gym-goers may lose weight faster. However, the psychological aspect is concerning. Appetite suppression can make it easier to eat clean, but it may take away the enjoyment of eating. Research suggests that retatrutide can affect mood, relationships, and motivation, although scientists are unsure why this happens.

What are the side effects of Retatrutide?

Current research shows that retatrutide can have several side effects, the most common being gastrointestinal—diarrhoea, nausea, vomiting, and constipation. The symptoms may be mild for some and severe for others. At present, at least one death has been reported due to drug use—the patient developed severe diarrhoea, and the case is currently being investigated.

How does retatrutide affect mental health?

Some media reports suggest that peptides like retatrutide affect more than just appetite—the medication acts on brain pathways involved in motivation and reward. This can influence one’s desire to eat food or drink alcohol. Research also indicates that it may affect libido and make individuals feel detached or emotionally flat in relationships.

In a significant case, the Supreme Court has allowed the medical termination of pregnancy of a 15-year-old girl who was over seven months pregnant.

Stressing that the choice of the pregnant woman must remain paramount, the SC bench led by Justice B V Nagarathna and Ujjal Bhuyan observed that a woman cannot be compelled to continue with an unwanted pregnancy merely on the ground that the child can be given up for adoption after birth.

However, AIIMS has sought a review of the order, citing medical ethics and the rights of an unborn child. The institution stated that it would lead to preterm delivery of a deformed baby needing prolonged NICU support.

The apex Court also issued a warning to the Union government of contempt proceedings if it failed to comply with its order, making it clear that the procedure must be carried out without delay.

What Is The case?

The SC directed the termination of a fetus over seven months old of the 15-year-old girl, who was in a consensual relationship with a 17-year-old, admitted at AIIMS Delhi since April 10.

In India, medical abortion is allowed up to 20-24 weeks of pregnancy under the Medical Termination of Pregnancy (MTP) Act. However, in this case, the medical termination was allowed, giving primacy to the reproductive autonomy of the minor.

The Justices made it clear that “no court ought to compel any woman, and more so a minor child, to carry a pregnancy to full term against her express will.”

“If the pregnant woman carrying an unwanted pregnancy is compelled to continue such a pregnancy, then the constitutional rights of the pregnant woman would be breached,” noted the court.

Also read: Why Miscarriage Needs Emotional Care At Par with Medical Treatment: Doctors Explain

However, Solicitor General Tushar Mehta, appearing before the court, told the bench that the child could be given up for adoption through CARA after being born. He told the bench that, as per medical reports, termination of pregnancy at this stage may be risky for both the mother and the unborn child.

But Justice Nagarathna warned that denying relief in such circumstances could expose women, especially minors, to grave risks, including resort to unregulated procedures that may cause irreversible harm.

The court also underscored the minor’s psychological distress, including reported attempts to take her own life, observing that forcing continuation of the pregnancy would have “long-lasting repercussions” on her mental health, education, social standing, and overall development, Law Beat reported.

Directing that the procedure be carried out at AIIMS Delhi with all necessary medical safeguards, the court required the minor’s guardian to submit an undertaking consenting to the termination.

Why Is AIIMS Asking For A Review Of The SC Order?

AIIMS said the “unborn viable child” cannot speak for itself and depends on the court’s parens patriae jurisdiction to protect its right to life, The Times of India reported.

AIIMS, in its plea, said, “The court’s order proceeds on the premise of termination of pregnancy; however, the medical reality, as disclosed by the post-order assessment, is that a living, viable child will be prematurely delivered into the world.”

AIIMS also cited a fresh medical board opinion, saying the fetus is viable and preterm delivery could cause long-term disabilities and pose a grave risk to the minor mother. It said if the baby is carried to term, the state could care for it till adoption.

Referring to a similar case, AIIMS said a prematurely delivered baby continues to need NICU support, suffered repeated sepsis, and remains dependent on tracheostomy care.

Artificial Intelligence can fast-track better diagnostics, and even a cure for Alzheimer’s Disease, said OpenAI CEO Sam Altman.

In an exclusive interview with TODAY, Altman also announced that the OpenAI Foundation is pledging $100 million to Alzheimer’s research.

“AI has the potential to dramatically speed up how we discover treatments, improve diagnostics, and hopefully get us closer to a cure,” he said.

“This is one of the hardest problems in medicine - and one that affects millions of families. We felt we could help accelerate progress,” Altman added.

OpenAI Commits $100 Million For Alzheimer’s Research

Alzheimer's disease is one of the most common forms of dementia, causing 60-70 percent of cases. It mostly affects adults over the age of 65 and is a leading cause of death and disability.

In a statement, OpenAI noted that Alzheimer’s is "one of the toughest problems in medicine".

"AI’s ability to reason across complex data could help researchers uncover new insights," it added.

Also read: This Common Vaccine At Higher Dose Can More Than Halve Alzheimer’s Risk In Older Adults

The company will partner with six research institutions to

• support and accelerate Alzheimer’s research
• generating new data,
• helping design new drugs,
• expanding possible paths to treatment, including repurposing existing FDA-approved molecules.

“The OpenAI Foundation’s Alzheimer’s research initiative represents more than scientific progress. It’s a hope for millions of people, families, and anyone concerned about brain health. We applaud bold investments that prioritize speed and rigor, because every day matters. We must accelerate breakthroughs that change what it means to live with, or be at risk for, Alzheimer’s," said Joanne Pike, President and CEO of the Alzheimer’s Association.

What Is Alzheimer’s Disease?

Alzheimer's disease is believed to be caused by the development of toxic amyloid and beta proteins in the brain, which can accumulate in the brain and damage cells responsible for memory.

While there is no clear cause of Alzheimer's disease, experts believe it can develop due to genetic mutations and lifestyle choices, such as physical inactivity, unhealthy diet, and social isolation.

Read More: The One Critical Thing You Should Do To Prevent Alzheimer's Disease

Early symptoms of Alzheimer's disease include forgetting recent events or conversations. Over time, Alzheimer's disease leads to serious memory loss and affects a person's ability to do everyday tasks.

There is no cure for this progressive brain disorder, and in advanced stages, loss of brain function can cause dehydration, poor nutrition, or infection. These complications can result in death.

About 8.8 million Indians aged 60 and above are estimated to be living with Alzheimer's disease. Over seven million people in the US, 65 and older, live with the condition, and over 100,00 die from it annually.